INTRODUCTION
Nonhuman primate models have been invaluable for developing hematopoietic gene therapy strategies for humans because gene transfer and stem cell clonality closely simulate that seen in patients. Gene therapy has now cured several hematopoietic diseases, as evidenced by successes for immunodeficiencies including X-linked severe combined immunodeficiency (SCID-X1), adenosine deaminase (ADA) deficiency and more recently chronic granulomatous disease (CGD). However, the risk of malignancy from vector integration is significant, as evidenced in the French SCID-X1 trial where 4 of 10 patients have developed leukemia that can be directly attributed to vector-mediated oncogene activation. 1 These findings have highlighted the importance of developing safer vector systems and developing animal models to evaluate vector integration and genotoxicity.
HIV-based lentiviral vectors are now being used in human trials because they offer several advantages for hematopoietic stem cell (HSC) gene therapy. Lentiviral vectors can enter the nucleus independent of mitosis, and are able to efficiently deliver complex transgenes such as globin genes that are not delivered efficiently by gammaretroviral vectors. 2 Lentiviral selfinactivating (SIN) vectors have deletions of enhancer and promoter sequences in the long terminal repeats (LTRs) designed to reduce the potential for transactivation of host genes and can be produced at high titer. While MLV-based gammaretroviral vectors favor integration into regions near promoters, 3 human immunodeficiency virus (HIV)-1-based lentiviral vectors integrate preferentially within genes. 4 Additionally, in canine and primate long-term repopulating cells, gammaretroviral vectors were found more frequently near (within 5,000 bp) of protooncogene start sites than HIV-based lentiviral vectors. 5, 6 A comparison of the genotoxicity of only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 4 SIN lentiviral vectors to gammaretroviral vectors with LTR-driven transgenes similar to the ones used in the SCID-X1 trial suggests that SIN lentiviral vectors may be safer, at least in a murine model. 7 We have previously shown that HIV-based lentiviral vectors can mediate gene transfer to longterm repopulating cells in the canine model, 8 but gene transfer into primate models including the rhesus macaque 9, 10 and the baboon has been inefficient, 11 likely due to host restriction factors including TRIM5α. 12 The rhesus macaque TRIM5α potently restricts HIV-1 replication by accelerating capsid uncoating after cell entry. 13 Restriction has also been seen with SIV based vectors in human hematopoietic cells. 14 We found that pigtailed macaque (Macaca nemestrina) CD34 + cells are highly permissive for transduction by HIV-1 derived vectors and describe efficient transduction of pigtailed macaque long-term repopulating cells using HIV-based lentiviral vectors at relatively low MOIs. This nonhuman primate model will be very useful for preclinical studies to evaluate the safety and efficacy of HIV-1 based vectors proposed for clinical studies. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Institutional Animal Care and Use Committee. Prior to hematopoietic cell collection, animals were administered recombinant human granulocyte colony stimulating factor (rhG-CSF, 100 µ g/kg), and also given recombinant human stem cell factor (rhSCF, 50 µg/kg) daily as subcutaneous injections for 5 days. On day 5, bone marrow was harvested from the humeri and/or femora. In preparation for transplantation, all animals received myeloablative total-body irradiation. Twenty-four hours after transplantation, the animals were started on intravenous G-CSF at 100 µ g/kg daily until the animals attained stable neutrophil engraftment with an absolute neutrophil count of >500/µL. Standard supportive care, including blood-product transfusions, fluid and electrolyte management, and antibiotics, were administered as needed.
MATERIALS AND METHODS

Animal
Hematopoietic recovery was monitored by daily complete blood counts. only.
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Comparison of HIV vector transduction in human, macaque and baboon cells in vitro.
Human HT1080 fibrosarcoma cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and with 100 U/mL penicillin and 100 µg/mL streptomycin. Macaque and baboon CD34 + cells were collected from rhG-CSF and stem cell factor (SCF) primed bone marrow, and human CD34 + cells were collected from G-CSF mobilized human volunteers. For CD34 + transductions, cells were cryopreserved and then thawed and immediately exposed to a lenti vector at an MOI of 5 or 50 in Iscove's modified Dulbecco's medium (IMDM) with 10%
FBS with 100 U/mL penicillin and 100 µg/mL streptomycin, supplemented with 100 ng/mL recombinant human stem cell factor (rhSCF), 100 ng/mL recombinant human Flt-3 ligand (rhuFlt3-L), 100 ng/mL interleukin (IL)-3, 100 ng/mL IL-6, 100 ng/mL thrombopoietin (TPO), and 100 ng/mL G-CSF in CH 296 coated tissue culture plates. After 18 hours the cells were replated in growth media plus cytokines, and percentage of cells expressing EGFP were determined by flow cytometry at day 3 or day 5 after transduction. FBS with 100 U/mL penicillin and 100 µg/mL streptomycin, supplemented with 100 ng/mL rhSCF, 100 ng/mL rhuFlt3-L, 100 ng/mL interleukin (IL)-3, 100 ng/mL IL-6, 100 ng/mL TPO, and 100 ng/mL G-CSF for 15-18 hours before transduction. For transduction, cells were supplemented with the same cytokine combination in flasks previously coated with the CH-296 fragment of fibronectin (Retronectin, Takara, Shiga, Japan). The transduction medium was also only.
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For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From supplemented with 4 µg/mL protamine sulfate. For animals J02043 and T04228 1 µg/mL cyclosporine was also added. The cells were exposed to an initial dose of vector for 6.5-8 hours and then exposed to second dose of vector overnight for 17-18 hours. Following transduction, cells were infused into recipients after myeloablative total body irradiation (TBI) conditioning.
Animal J02043 received a myeloablative dose of 1020 cGy TBI in two doses of 510 cGy, and animals J02370 and T04228 received 800 cGy in 4 doses of 200 cGy from a single source linear X-ray accelerator (Linac Systems, Inc., Lakewood, NJ, USA) at 7 cGy/minute. After infusion of autologous gene-modified cells, the animals received recombinant G-CSF at 100 µg/kg daily until the animals maintained an ANC of >500/µL. The animals also received standard supportive care including intravenous hydration and broad spectrum antibiotics (ceftazadime, vancomycin, gentamicin), an antiviral agent (acyclovir), an antifungal agent (fluconozol), and transfusions with irradiated pigtailed macaque whole blood for treatment of post-transplant thrombocytopenia.
CFU assay. Transduced and mock-transduced CD34-enriched cells were cultured in a doublelayer agar culture system as previously described.
6,18 Colonies were enumerated and evaluated for GFP expression on day 14 of culture using fluorescence microscopy. 
Retrovirus
RESULTS
Efficient transduction of pigtailed macaque cells in vitro. We had previously observed persistent but low level transduction of baboon repopulating cells (Papio cynocephalus anubis)
using HIV-1 derived lentiviral vectors, 11 likely due to restriction mediated by TRIM5α. however, as would be expected at the low MOI, the rhesus cells were refractory to transduction 
Engraftment after transplantation of lenti vector transduced cells.
We performed a series of three transplants in pigtailed macaques using HIV-based vectors. In the three animals a stable absolute neutrophil count (ANC) >500/µL was reached by either day 10 or day 11 ( Table 1) . A platelet count >20,000/µL was reached at an average of 29 days. were transplanted with cells exposed to an EGFP-expressing vector, so the transduction efficiency of hematopoietic repopulating cells after transplantation could be accurately measured by flow-cytometric detection of EGFP in peripheral blood (PB) cells (Fig. 2C,D) . We observed stable long term (>450, >441 days) transgene expression with high marking levels in both granulocytes and lymphocytes. Long-term marking (over 90 days post-transplant) rose to as high as 36% and 50% in T04228 and J02370, respectively, in short-lived granulocytes, and was Gene transfer rates after transplantation were also determined at several time points by real-time PCR for all three monkeys (Fig. 3A) using primers specific for the lentiviral cis-acting region.
The average proviral copy number was determined using a control cell line that contains a single lentiviral vector provirus. The real-time PCR analysis showed that monkey J02043 which received cells transduced with a vector that did not encode a fluorescent marker also had very high marking with an average proviral copy number of 1.3 that varied between 0.9 and 1.4. The EGFP-expressing monkey J02370 had an average proviral copy number of 0.6 that varied between 0.5 and 0.75, and monkey T04428 had an average proviral copy number of 0.4 that Fig. 3B) . However, the marking levels were approximately 2-fold lower than observed by flow cytometry or real-time PCR. This difference might be explained in part by differences in loading of the DNA prior to Southern blot analysis (data not shown). It should be noted that all three monkeys contained a mutant MGMT gene for in vivo selection, but the marking data presented here was obtained without any in vivo selection.
Analysis of gene expression in hematopoietic lineages. To assess gene expression in different hematopoietic lineages, PB cells were labeled with antibodies against granulocytes (CD13), T lymphocytes (CD3), B lymphocytes (CD20), and analyzed by flow cytometry. We also determined the marking levels in BM-derived CD34
+ cells. Figure 4A shows representative only.
For ) and 116 and 441 days (T04228) after transplantation. Sustained EGFP expression could be detected in all subsets examined and flow cytometry profiles are shown in Figure 4B . In both monkeys we were also able to detect fluorescence positive platelets and fluorescence positive erythrocytes (Fig. 4C,D) . Since EGFP fluorescence intensity in these cell populations is significantly lower than in white blood cells, these data likely underestimate marking in erythropoietic progenitors. Both of these cell populations are enucleated, and are therefore transcriptionally inactive, so the EGFP protein half-life largely dictates the level of expression.
We have monitored these animals by performing complete blood counts to monitor the potential development of myeloproliferation, lymphoproliferation or leukemia. To date there has been no evidence of malignancy and all three animals remain healthy.
Clonality of transduced macaque repopulating cells. LAM-PCR was performed on the PB
from all three animals to evaluate the clonality of the engrafted cells. All three monkeys engrafted with a polyclonal set of repopulating cells as evidenced by multiple LAM-PCR fragment sizes (Fig. 5) . We have identified over 235 unique integration sites in these monkeys and a detailed analysis of these integration sites has been published elsewhere.
6 Animals J02370
and J02043 have since been moved to another study but all monkeys are currently alive and well at 463 (T04228), 698 (J02370), and 981 days (J02043) after transplantation. TRIM5α isoforms likely explain why we were able to efficiently transduce pigtailed macaque cells at low MOIs using the wild-type HIV-1 capsid which is potently restricted by rhesus TRIM5α. 12 The differences between rhesus and pigtailed macaque TRIM5α also likely explains the higher marking we observed here relative to previous studies using HIV-based vectors in the rhesus macaque model where long-term marking was typically lower than 3% with one animal having marking levels of approximately 10% and 2% in granulocytes and lymphocytes respectively. 9, 10 In three monkeys that received autologous CD34 + cells transduced with VSV-G pseudotyped cytometry. This is a remarkable level considering the relatively short transduction period (48 h) and the low MOIs (5-10) used. Engraftment was relatively rapid with a mean of 10.3 days to an ANC > 500/µL and was stable over time in both monkeys in which the EGFP fluorescent marker could be followed by flow cytometry of PB leukocytes. In all three monkeys real-time PCR yielded consistently high level marking that could be readily detected by Southern blot analysis.
The most accepted assay for the transduction of stem cells is the ability to deliver genes to large animal repopulating cells that differentiate into all blood lineages and persist long term. We were able to track marking in the three monkeys for 5, 15, and 15 months, and for animals J02370 and T04228, EGFP-expressing cells were detected in all hematopoietic lineages including red blood cells and platelets. These data strongly suggest that long-term, multipotent repopulating cells were transduced with the VSV-G pseudotyped lentiviral vectors. A previous study showed efficient gene transfer to rhesus macaque repopulating cells using simian immunodeficiency virus vectors pseudotyped with an amphotropic receptor 14 Gene transfer levels detected in PB were similar to those determined in bone marrow leukocytes (Fig. 4A) . These data suggest that there is no block in differentiation or elimination of mature MOIs of 5 to 10 resulted in relatively low vector provirus copy numbers and provided robust transgene expression without significant silencing.
In conclusion, we report efficient and reproducible transduction of long-term, multipotent primate repopulating cells in a short overnight transduction protocol using HIV-based lentiviral vectors. These data show that using our described protocol, clinically-relevant marking can be obtained in a primate model. Our data also show that pigtailed macaques are an excellent preclinical model for HSC gene therapy using HIV-based vectors. The relatively short transduction protocol described here should be particularly important for diseases such as
Fanconi anemia where maintenance of stem cells during ex vivo transduction may be an obstacle only.
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